Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.
Corsera Health has raised $80.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.
Corsera Health's investors include Forbion Capital Partners, Population Health Partners, John Maraganore.
Corsera Health is headquartered in Boston, United States.
Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.
Corsera Health is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Corsera Health — Funding & Investors." VCBacked, January 7, 2026, https://www.vcbacked.co/company/corsera-health-boston-2. Accessed October 21, 2026.
VCBacked. (2026). Corsera Health — Funding & Investors. Retrieved October 21, 2026, from https://www.vcbacked.co/company/corsera-health-boston-2
{{cite web |title=Corsera Health — Funding & Investors |url=https://www.vcbacked.co/company/corsera-health-boston-2 |website=VCBacked |access-date=October 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated